Just Evotec Biologics, the biologics division of German-based Evotec, has opened a new J.POD biologics development facility in Toulouse, France. The facility is located in Evotec's Campus Curie and will improve the company's essential clinical and commercial biologics manufacturing capacity.

Spanning 15,000sqm, the new facility was built over 18 months and will be able to deliver 2 metric tons of biotherapeutics. The facility houses specialized labs for quality assurance and process development for both clinical and commercial products. It also provides a storage facility and workspaces.

Dr Christian Wojczewski, CEO of Evotec, highlighted the company's collaboration with the public sector, "We are very thankful for the support from the French government, the Occitanie Region, Bpifrance, the Haute-Garonne prefecture and the Toulouse Métropole for helping us achieve this milestone at our Campus Curie in Toulouse."

Dr Linda Zuckerman, EVP and global head of biotherapeutics at Just Evotec Biologics added, “With this facility, we extend our capacity to discover and develop groundbreaking biologics but also, with our partners, deliver them promptly to patients in need. Our Toulouse-based team at Just Evotec Biologics deserves immense credit for bringing the J.POD facility and its capabilities to France and the EU.”

The construction of J.POD Toulouse has benefitted from funding provided as part of 'Le Programme d'investissements d'avenir' (Future Investment Program). It has also been supported economically by the Occitanie Region.

"Evotec opens first European biologics facility in France" was originally created and published by Investment Monitor, a GlobalData owned brand.

 

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.